Milestone Pharmaceuticals Reports Q2 2026 Financial Results

What Happened
Milestone Pharmaceuticals Inc. (MIST) filed a Form 8-K on August 12, 2026 to announce its financial results for the quarter ended June 30, 2026. The company issued a press release with those results and business highlights; that press release is furnished as Exhibit 99.1 to the 8-K and is incorporated by reference. The filing is reported under Item 2.02 (Results of Operations and Financial Condition).

Key Details

• Filing date: August 12, 2026; reporting period: quarter ended June 30, 2026.
• Item reported: 2.02 — Results of Operations and Financial Condition.
• The company’s press release with the Q2 2026 results is furnished as Exhibit 99.1 to the Form 8-K.
• Exhibit list also includes Inline XBRL cover page tags (Exhibit 104).

Why It Matters
This 8-K provides Milestone’s latest quarterly results and business updates that investors use to assess recent operating performance, revenue trends, cash position, and any clinical or corporate highlights. Retail investors should read the attached press release (Exhibit 99.1) for the specific figures (revenue, net loss/gain, cash runway, and management commentary) and monitor subsequent SEC filings for detailed financial statements and disclosures.